G1 Therapeutics (GTHX) News Today → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free GTHX Stock Alerts $3.99 -0.20 (-4.77%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineG1 Therapeutics (GTHX) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - April 24 at 5:49 AMG1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profitfinance.yahoo.com - April 19 at 2:39 PMG1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Sold by Raymond James & Associatesmarketbeat.com - April 18 at 4:09 AMG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024finance.yahoo.com - April 17 at 9:28 AMG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024globenewswire.com - April 17 at 9:00 AMBuy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment Appealmarkets.businessinsider.com - April 12 at 2:35 PMBreaking Down G1 Therapeutics: 5 Analysts Share Their Viewsmarkets.businessinsider.com - April 12 at 2:35 PMG1 Therapeutics (NASDAQ:GTHX) Given "Buy" Rating at Needham & Company LLCmarketbeat.com - April 12 at 8:24 AMG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 10:30 AMG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 1 at 4:20 PMG1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting Measuresmarketwatch.com - March 22 at 11:29 PMWhy G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscapeseekingalpha.com - March 22 at 6:29 PMG1 Therapeutics, Inc. (NASDAQ:GTHX) CFO Sells $19,771.94 in Stockinsidertrades.com - March 21 at 10:33 AMJohn W. V. Umstead Sells 6,547 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) Stockmarketbeat.com - March 20 at 8:13 PMShort Interest in G1 Therapeutics, Inc. (NASDAQ:GTHX) Drops By 12.6%marketbeat.com - March 16 at 10:40 PMGTHX Apr 2024 3.000 callfinance.yahoo.com - March 16 at 12:54 AMGTHX Apr 2024 3.500 putfinance.yahoo.com - March 16 at 12:54 AMGTHX Mar 2024 3.000 putfinance.yahoo.com - March 6 at 11:21 PMG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 1 at 4:20 PMG1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 1 at 10:53 AMAnalysts Offer Predictions for G1 Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:GTHX)marketbeat.com - March 1 at 8:02 AMBuy Rating Justified by G1 Therapeutics’ Strong Q4 Earnings and Cosela’s Market Tractionmarkets.businessinsider.com - February 29 at 1:24 PMG1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 29 at 1:24 PMQ4 2023 G1 Therapeutics Inc Earnings Callfinance.yahoo.com - February 29 at 1:56 AMG1 Therapeutics Inc (GTHX)investing.com - February 28 at 8:55 PMGTHX Jul 2024 2.500 putfinance.yahoo.com - February 28 at 3:55 PMG1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87Mmsn.com - February 28 at 3:55 PMForecasting The Future: 5 Analyst Projections For G1 Therapeuticsmarkets.businessinsider.com - February 28 at 3:55 PMG1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023finance.yahoo.com - February 28 at 10:55 AMG1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsglobenewswire.com - February 28 at 6:30 AMG1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 27 at 8:30 AMG1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutionsfinance.yahoo.com - February 17 at 10:29 AMG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024finance.yahoo.com - February 15 at 3:20 PMG1 Therapeutics, Inc. (NASDAQ:GTHX) to Post FY2025 Earnings of ($0.52) Per Share, Wedbush Forecastsmarketbeat.com - February 15 at 8:44 AMG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024globenewswire.com - February 15 at 8:30 AMGTHX Feb 2024 7.500 putfinance.yahoo.com - February 14 at 10:55 PMG1 Therapeutics stock sinks 53% in wake of study updatemsn.com - February 13 at 9:16 PMG1 Therapeutics Shares Down 54% After Cancer Study Update, Wedbush Price Target Cutmarketwatch.com - February 13 at 4:16 PMG1 Therapeutics Sees Unusually High Options Volume (NASDAQ:GTHX)marketbeat.com - February 13 at 12:54 PMG1 Therapeutics, CareCloud among healthcare moversmsn.com - February 13 at 10:41 AMWhy Is G1 Therapeutics (GTHX) Stock Down 45% Today?investorplace.com - February 13 at 9:12 AMWedbush Cuts G1 Therapeutics (NASDAQ:GTHX) Price Target to $4.00marketbeat.com - February 13 at 8:41 AMShares G1 Therapeutics Tumble 46% Following Update to Phase 3 Breast Cancer Studymarketwatch.com - February 12 at 8:01 PMG1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committeefinance.yahoo.com - February 12 at 8:01 PMG1 Therapeutics Options Trading: A Deep Dive into Market Sentimentbenzinga.com - February 12 at 3:00 PMG1 Therapeutics, Inc. (GTHX)ca.finance.yahoo.com - January 31 at 9:57 AMG1 Therapeutics, Inc. (NASDAQ:GTHX) Short Interest Updatemarketbeat.com - January 29 at 2:38 AMNeedham & Company LLC Reaffirms Buy Rating for G1 Therapeutics (NASDAQ:GTHX)marketbeat.com - January 24 at 8:36 AMG1 Therapeutics: New Financials And Big Data Readout Alertseekingalpha.com - January 9 at 10:14 AMG1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 8 at 7:57 AM Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… GTHX Media Mentions By Week GTHX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GTHX News Sentiment▼1.480.44▲Average Medical News Sentiment GTHX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GTHX Articles This Week▼32▲GTHX Articles Average Week Get G1 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABEO News Today GALT News Today DSGN News Today GBIO News Today ZVRA News Today NCNA News Today OVID News Today CDT News Today SKYE News Today RIGL News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GTHX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
